Efficacy and Safety of Sparsentan Compared With Irbesartan in Patients With Primary Focal Segmental Glomerulosclerosis: Randomized, Controlled Trial Design (DUET)

INTRODUCTION: Primary focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome and end-stage renal disease. There are no US Food and Drug Administration−approved therapies for FSGS, and treatment often fails to reduce proteinuria. Endothelin is an important factor in the pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Komers, Radko, Gipson, Debbie S., Nelson, Peter, Adler, Sharon, Srivastava, Tarak, Derebail, Vimal K., Meyers, Kevin E., Pergola, Pablo, MacNally, Meghan E., Hunt, Jennifer L., Shih, Alvin, Trachtman, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678638/
https://www.ncbi.nlm.nih.gov/pubmed/29142983
http://dx.doi.org/10.1016/j.ekir.2017.02.019

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5678638/
https://www.ncbi.nlm.nih.gov/pubmed/29142983
http://dx.doi.org/10.1016/j.ekir.2017.02.019

Ejemplares similares